Warner Greene, MD, PhD

Headshot of Warner Greene
User Profile Photo

Warner Greene, MD, PhD

User Profile Name
Director, Gladstone Center for HIV Cure Research
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Warner C. Greene, MD, PhD is Director of the Gladstone Center for HIV Cure Research, Senior Investigator, and Nick and Sue Hellmann Distinguished Professor of Translational Medicine at the Gladstone Institute of Virology and Immunology (GIVI). He is the Founding and Emeritus Director of GIVI. Dr. Greene is also Professor of Medicine, Microbiology and of Immunology at UCSF. Dr. Greene is a member of the Institute of Medicine of the National Academies and a fellow of the American Academy for the Advancement of Science. He also serves as Co-Director of the UCSF-Gladstone Center for AIDS Research, and has served as a Councilor and President of the Association of American Physicians. Dr. Greene earned a bachelor’s degree at Stanford University and an MD/PhD at Washington University School of Medicine. He took his internship and residency training in Medicine at the Massachusetts General Hospital at Harvard. After serving as a Senior Investigator at the National Cancer Institute and a Professor of Medicine and Howard Hughes Investigator at Duke University Medical Center, Dr. Greene accepted his current position as the Founding Director of the Gladstone Institute of Virology and Immunology in 1991. The ongoing research in Dr. Greene’s laboratory focuses on the molecular mechanisms underlying HIV pathogenesis, latency, and transmission. He is the author of more than 380 scientific papers and has been recognized as one of the 100 Most Cited Scientists in the world. In 2007, Dr. Greene expanded his work to include global health in sub-Saharan Africa in his service as president and executive chairman of the Accordia Global Health Foundation. Accordia established the Infectious Diseases Institute at Makerere University in Uganda, which has trained thousands of African health care workers, is caring for 30,000 HIV-infected patients, and has brought health care to nearly 500,000 people living in remote rural regions of Uganda. In 2016, Accordia merged with Africare.
CTSI Profile Bio

Displaying 201 - 225 of 386

  1. Miller MD, Feinberg MB, Greene WC. The HIV-1 nef gene acts as a positive viral infectivity factor. Trends Microbiol. 1994 Aug; 2(8):294-8.
  2. Goldsmith MA, Xu W, Amaral MC, Kuczek ES, Greene WC. The cytoplasmic domain of the interleukin-2 receptor beta chain contains both unique and functionally redundant signal transduction elements. J Biol Chem. 1994 May 20; 269(20):14698-704.
  3. Williamson P, Merida I, Greene WC, Gaulton G. The membrane proximal segment of the IL-2 receptor beta-chain acidic region is essential for IL2-dependent protein tyrosine kinase activation. Leukemia. 1994 Apr; 8 Suppl 1:S186-9.
  4. Sun SC, Ganchi PA, Béraud C, Ballard DW, Greene WC. Autoregulation of the NF-kappa B transactivator RelA (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. Proc Natl Acad Sci U S A. 1994 Feb 15; 91(4):1346-50.
  5. Béraud C, Sun SC, Ganchi P, Ballard DW, Greene WC. Human T-cell leukemia virus type I Tax associates with and is negatively regulated by the NF-kappa B2 p100 gene product: implications for viral latency. Mol Cell Biol. 1994 Feb; 14(2):1374-82.
  6. Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med. 1994 Jan 01; 179(1):101-13.
  7. Ganchi PA, Sun SC, Greene WC, Ballard DW. A novel NF-kappa B complex containing p65 homodimers: implications for transcriptional control at the level of subunit dimerization. Mol Cell Biol. 1993 Dec; 13(12):7826-35.
  8. Stein B, Baldwin AS, Ballard DW, Greene WC, Angel P, Herrlich P. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J. 1993 Oct; 12(10):3879-91.
  9. Greene WC. AIDS and the immune system. Sci Am. 1993 Sep; 269(3):98-105.
  10. Bogerd H, Greene WC. Dominant negative mutants of human T-cell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo. J Virol. 1993 May; 67(5):2496-502.
  11. Kuziel WA, Ju G, Grdina TA, Greene WC. Unexpected effects of the IL-2 receptor alpha subunit on high affinity IL-2 receptor assembly and function detected with a mutant IL-2 analog. J Immunol. 1993 Apr 15; 150(8 Pt 1):3357-65.
  12. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science. 1993 Mar 26; 259(5103):1912-5.
  13. Merida I, Williamson P, Kuziel WA, Greene WC, Gaulton GN. The serine-rich cytoplasmic domain of the interleukin-2 receptor beta chain is essential for interleukin-2-dependent tyrosine protein kinase and phosphatidylinositol-3-kinase activation. J Biol Chem. 1993 Mar 25; 268(9):6765-70.
  14. Hammes SR, Greene WC. Multiple arginine residues within the basic domain of HTLV-I Rex are required for specific RNA binding and function. Virology. 1993 Mar; 193(1):41-9.
  15. Doerre S, Sista P, Sun SC, Ballard DW, Greene WC. The c-rel protooncogene product represses NF-kappa B p65-mediated transcriptional activation of the long terminal repeat of type 1 human immunodeficiency virus. Proc Natl Acad Sci U S A. 1993 Feb 01; 90(3):1023-7.
  16. Ganchi PA, Sun SC, Greene WC, Ballard DW. I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding. Mol Biol Cell. 1992 Dec; 3(12):1339-52.
  17. Mills GB, Arima N, May C, Hill M, Schmandt R, Li J, Miyamoto NG, Greene WC. Neither the LCK nor the FYN kinases are obligatory for IL-2-mediated signal transduction in HTLV-I-infected human T cells. Int Immunol. 1992 Nov; 4(11):1233-43.
  18. Feinberg MB, Greene WC. Molecular insights into human immunodeficiency virus type 1 pathogenesis. Curr Opin Immunol. 1992 Aug; 4(4):466-74.
  19. Walker WH, Stein B, Ganchi PA, Hoffman JA, Kaufman PA, Ballard DW, Hannink M, Greene WC. The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation. J Virol. 1992 Aug; 66(8):5018-29.
  20. Weichselbraun I, Berger J, Dobrovnik M, Bogerd H, Grassmann R, Greene WC, Hauber J, Böhnlein E. Dominant-negative mutants are clustered in a domain of the human T-cell leukemia virus type I Rex protein: implications for trans dominance. J Virol. 1992 Jul; 66(7):4540-5.
  21. Arima N, Kuziel WA, Grdina TA, Greene WC. IL-2-induced signal transduction involves the activation of nuclear NF-kappa B expression. J Immunol. 1992 Jul 01; 149(1):83-91.
  22. Kaufman PA, Weinberg JB, Greene WC. Nuclear expression of the 50- and 65-kD Rel-related subunits of nuclear factor-kappa B is differentially regulated in human monocytic cells. J Clin Invest. 1992 Jul; 90(1):121-9.
  23. Smith MR, Greene WC. Characterization of a novel nuclear localization signal in the HTLV-I tax transactivator protein. Virology. 1992 Mar; 187(1):316-20.
  24. Ballard DW, Dixon EP, Peffer NJ, Bogerd H, Doerre S, Stein B, Greene WC. The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression. Proc Natl Acad Sci U S A. 1992 Mar 01; 89(5):1875-9.
  25. Arima N, Molitor JA, Smith MR, Kim JH, Daitoku Y, Greene WC. Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of kappa B enhancer-binding proteins: evidence for a pretranslational component of regulation. J Virol. 1991 Dec; 65(12):6892-9.